T ransplant arteriosclerosis (TA), with its distinctive concentric intimal hyperplasia, is characterized by the diffuse narrowing and occlusion of vessels in the allograft. The pathogenesis of TA involves a combination of peritransplant events, infections, alloimmunity, and conventional risk factors of atherosclerosis (1) . TA develops specifically in allografts, which suggests the critical role of an immunological response. Using current immunosuppressive agents, the allograft may be relatively free of parenchymal cellular rejection but simultaneously exhibit TA (2) . Therefore, novel therapeutic strategies for preventing TA are required to enhance the survival rate of solid-organ transplant recipients.
Mesenchymal stem cells (MSCs), which modulate various aspects of innate and adaptive immunity, have been applied to the treatment of autoimmune diseases (3, 4) , allergic airway inflammation (5) , and allograft rejection (6) (7) (8) . In adaptive immunity, MSCs tilt T cell responses toward regulatory T cell (Treg) profiles both in vitro (9-13) and in vivo. Tregs are characterized by their suppressive and anergic properties. The two most relevant classes of CD4 + Tregs are CD4 + CD25 + Foxp3 + Tregs (14) and regulatory T type 1 (T R 1) cells (15) . T R 1 cells are defined by their suppression of Ag-specific immune responses in an IL-10-dependent manner (15) , without Foxp3 expression (16) . The canonical profile initially described for T R 1 cells is IL-10 + TGF-b + IL-4 2 IL-2 2 IFNg +/2 (15) . Subsequently, a subpopulation of the IL-10-secreting T R 1 cells was found to produce substantial levels of IFN-g (17) (18) (19) , and they were designated "T R 1-like cells" (20) (21) (22) (23) . MSCs were demonstrated to drive the generation of Foxp3 + Tregs. Recently, MSCs were reported to expand T R 1 cells bearing the CD4 + CD25
+ IL-10 + phenotype (24) . Whether MSCs achieve immune tolerance by inducing T R 1-like cells with a CD4 + IL-10 + IFN-g + signature remains unknown. The modulating effect of MSCs on allogeneic responses is ascribed, in part, to cyclooxygenase (COX)-derived PGE 2 (10, 25, 26) . The biosynthesis of PGE 2 by MSCs is not only constitutive, it also is augmented by inflammatory stimuli (10, 27) . Certain studies suggested that inflammation, through the induction of COX-2 and IDO, is a prerequisite for licensing MSCs to become immunosuppressive (28) (29) (30) . IDO catalyzes the rate-limiting step of tryptophan (Trp) degradation along the kynurenine (KYN) pathway (31) , and both the reduction in local Trp concentration and the generation of Trp metabolites contribute to the regulatory effects of IDO. PGE 2 was demonstrated to foster the outgrowth of T R 1 cells in the tumor microenvironment (32, 33) . IDO expression in APCs was suggested to induce IL-10-secreting Tregs (34) . Thus, COX-PGE 2 and IDO may be significant molecules for the generation of T R 1 cells.
We recently reported that bone marrow-derived MSCs are effective in suppressing TA and that they are associated with an enhanced expression of tissue levels of IL-10, IFN-g, and IDO but not of Foxp3 (35) . These results led us to propose that the control of TA by MSCs may be mediated by inducing a subtype of Tregs, such as T R 1-like cells. In this study, we demonstrate the induction of IL-10 + IFN-g + CD4 + cells by MSCs in an allogeneic MLR. Furthermore, MSCs render a population of low-proliferative CD4 + cells to commit to T R 1-like cells. We also provide evidence that MSCs induce T R 1-like cells and mediate immunosuppression in vitro through activation of the COX-PGE 2 and IDO pathways. Finally, the results indicate that dual treatment with PGE 2 and T R 1-like cells alleviates intimal proliferation in porcine models of allogeneic femoral arterial transplants.
Materials and Methods

Animals
Adult Taiwanese Lanyu minipigs (25-40 kg) , procured from the Animal Propagation Station, Livestock Research Institute (Taitung, Taiwan), were maintained in the Laboratory Animal Center of National Taiwan University. All minipigs were used in the study according to the Guidelines for Animal Care. The experimental protocol was approved by the Institutional Animal Care and Use Committee (approval number 20060178).
Reagents
For flow cytometry analysis (FACSCalibur; BD) and FACS sorting (FACSAria; BD), the following Abs for positive staining were used: anti-CD4a-FITC (MIL17; Serotec), anti-CD4a-PE (74-12-4; BD), anti-IL-10 (262715; R&D Systems), anti-IFN-g-PerCP-Cy5.5 (P2G10; BD), anti-Foxp3-allophycocyanin (FJK-16S; eBioscience), and anti-IDO (H-110; Santa Cruz). The Abs used for isotype-control staining were mIgG2b-FITC (MG2b-57; BioLegend), mIgG2b-PE (MG2b-57; BioLegend), mIgG2b (eBioscience), mIgG1-PerCP-Cy5.5 (P3.6.2.1; eBioscience), rat IgG2a-allophycocyanin (eBioscience), and normal rabbit IgG (Santa Cruz).
Preparation of porcine bone marrow-derived MSCs and conditioned medium
MSCs were derived from the bone marrow aspirates of minipigs and grown in MSC medium consisting of aMEM (Invitrogen) and 10% FBS (Invitrogen) supplemented with basic fibroblast growth factor and epithelial cell growth factor (10 ng/ml each; R&D Systems).
To prepare the MSC conditioned medium (CM), MSCs were initially plated in MSC medium to reach 50% confluence, followed by seeding in MLR medium composed of RPMI 1640 medium (Invitrogen) supplemented with 10% heat-inactivated adult porcine serum (Invitrogen) and 10% KNOCKOUT SR (Invitrogen). After 72 h, cell culture supernatant was harvested and frozen as MSC CM.
One-way MLR
We used MLR as a cell model to assess the potential of MSCs to induce T R 1-like cells.
PBMCs were isolated from minipig blood using density-gradient centrifugation (Ficoll-Paque; GE Healthcare Bio-Sciences AB). The one-way MLR assay was performed in a 96-well round-bottom plate, as we described previously (35) . In brief, 1 3 10 5 responder cells and 1 3 10 5 stimulator cells were plated in each well. MSCs (5 3 10 4 cells/well) treated with Mitomycin-C (25 mg/ml) or MSC CM (0.1 ml/well) were added to the coculture. On the fourth day of coculture, cells were pulsed with 1 mCi/ ) were suspended in 1 ml PBS containing CFSE (5 mM; SigmaAldrich) and shaken at 10 rpm for 8 min at room temperature, to which cold PBS containing 2% FBS was added to stop the labeling process.
CSFE fluorescence intensity was measured by FACS analysis. To evaluate the influence of COX and/or IDO inhibitors on MSC action, indomethacin (IDM; 50 mM), celecoxib (25 mM), and/or 1-methyl-L-tryptophan (L-1-MT; 1 mM; all from Sigma-Aldrich) were added to the MSC-MLR coculture. Where indicated, dinoprostone or misoprostol acid (MPA; both from Sigma-Aldrich) at various concentrations was used to investigate the role of PGE 2 .
Transwell experiments
Transwell experiments were conducted using HTS Transwell-96 Well Permeable Supports (Corning). Responder and stimulator PBMCs (10 5 cells/100 ml MLR medium/well) were cultivated in a 96-well roundbottom plate, and MSCs (5 3 10 4 cells/100 ml MLR medium/insert) were seeded onto the semipermeable membrane of Transwell inserts with a 1.0-mm pore size.
Isolation of MSC-primed responder CD4
+ cells The immunosuppressive properties of CD4 + R were evaluated using a subsequent allogeneic MLR (second MLR), in which the responder and stimulator PBMCs are identical to those in the first MLR. CD4 + R sorted from the first MLR were treated with mitomycin-C (25 mg/ml) and added at a cell ratio of 1:1 (CD4 + R/responder PBMCs). To investigate the role of IL-10 in CD4 + R-mediated immunosuppression, neutralizing mAb against IL-10 (10 mg/ml; Invitrogen) or isotype control IgG1 (10 mg/ml; BioLegend) was added to the second MLR. To assess the allogeneic responsiveness of CD4 
Intracellular staining
Cells were stained for Foxp3 and IDO using an intracellular staining buffer set (eBioscience), following the manufacturer's instructions. For cytokine staining, the protein transport inhibitor monensin (1 ml/ml; eBiosciences) was added for the final 6 h of the MLR. In selected experiments, cells were restimulated for 4 h with phorbol 12-myristate 13-acetate (50 ng/ml) and ionomycin (500 ng/ml; both from Sigma-Aldrich). After fixation with 4% paraformaldehyde, cells were permeabilized with 0.1% saponin (eBioscience) and stained for IL-10 and IFN-g.
ELISAs
Using commercially available kits, we analyzed the levels of IL-10, IFN-g, and PGE 2 in supernatants harvested at specified time points in the MLR. The detection limits of the ELISA kits were 7.8 pg/ml for IL-10 (Invitrogen), 39 pg/ml for IFN-g (R&D Systems), and 7.8 pg/ml for PGE 2 (R&D Systems).
Preparation of cell lysates and analyte extraction
Cell pellets prepared from the MLR were washed twice with PBS, resuspended in 50% (v/v) methanol (1 3 10 6 cells/ml), and vortexed for 2 h at room temperature. After centrifugation at 2300 3 g for 5 min, the supernatants were concentrated to dry under a nitrogen stream. The residues were reconstituted in deionized water for further analysis.
Liquid chromatography coupled with tandem mass spectrometry
Standards (500 ng/ml) for Trp and KYN (both Sigma-Aldrich) were prepared in 50% (v/v) methanol. Liquid chromatography coupled with tandem mass spectrometry was performed using an ultra-HPLC system (Agilent 1290) connected to a triple quadrupole tandem mass spectrometer (Agilent 6460) outfitted with an Agilent Jet Stream electrospray ionization source operating in the positive mode. An Agilent Poroshell EC-C18 (100 mm 3 2.1 mm inner diameter column; 2.7 mm particle size) was used for reversephase chromatography. 
Pig model of femoral arterial transplantation
Femoral arterial transplantation was performed as described (35) . Minipigs undergoing femoral arterial transplantation were divided into four experimental groups (n = 3 for each group): untreated group, PGE 2 group, MSCprimed CD4 + R cell group, and PGE 2 plus MSC-primed CD4 + R cell group. PGE 2 was administered in two stages. In the perioperative stage, dinoprostone (100 mg) was infused i.v. for 30 min just at the time of graft anastomosis, and misoprostol (200 mg; Pfizer) was administered orally in the postoperative stage four times daily until graft harvest. MSC-primed CD4 + R cells (2 3 10 6 cells in 1 ml divided into 10 injections for each graft) were injected into the skeletal muscle surrounding the vascular grafts.
Histological analysis
Formalin-fixed vascular grafts were embedded in paraffin, cross-sectioned, deparaffinized, rehydrated, and subjected to H&E or orcein staining. Intimal hyperplasia of vascular grafts was determined from computer images of orcein-stained cross-sections. The area surrounded by internal elastic lamina (IELA) and the luminal area (LA) were calculated by an image-analysis program (Image J, Version 1.46r, NIH Image). The severity of intimal hyperplasia was calculated by the formula: [(IELA 2 LA)/ IELA] 3 100%.
Statistical analysis
All data are expressed as mean 6 SD. Statistical analysis was performed using Prism 5 software (GraphPad Software, San Diego, CA). Group differences were assessed by the t test, and three or more data sets were compared using one-way ANOVA with Bonferroni multiple comparison for measuring significance. A p value ,0.05 was considered statistically significant.
Results
Abortive alloresponse in the presence of MSCs is associated with elevation of IL-10 and IFN-g but not Foxp3
The one-way MLR assay showed that MSCs at a ratio of 1:2 (MSC/ responder PBMCs) significantly reduced [ 3 H]thymidine incorporation of allostimulated responder PBMCs (n = 3, p , 0.001, Supplemental Fig. 1A ). In parallel, MSCs restrained the division of the CFSE-labeled responder PBMCs over the entire culture period (Supplemental Fig. 1B, 1C ). These findings suggest that MSCs attenuate allogeneic lymphocyte proliferation. IL-10 and IFN-g in the culture supernatant of MSCs alone were nearly undetectable (data not shown). The level of IL-10 (n = 3, p , 0.001, Fig. 1A ) and IFNg (n = 3, p , 0.001, Fig. 1B ), but not that of intranuclear Foxp3 (n = 3, p = 0.475, Fig. 1C, 1D) , of the MLR were upregulated by MSCs. These results suggest that MSCs induce a subset of PBMCs to express IL-10 and IFN-g but not Foxp3. + cells in the Transwell system (4.7 6 0.2% versus 0.9 6 0.5%, n = 3, p , 0.001, Supplemental Fig. 2C, 2D) . Similarly, the CM of MSCs expanded IL-10 + IFN-g + CD4 + cells .3-fold over the control MLR medium (3.6 6 0.5% versus 0.9 6 0.5%, n = 3, p , 0.001, Supplemental Fig. 2C, 2D Fig. 2A, 2B) . Corresponding to the increase in IDO + cells, the enzyme activity of IDO was enhanced in MSC-treated PBMCs in the MLR (Fig.  2C) . PGE 2 was reported to promote immune tolerance by regulating IDO expression (36, 37) . To corroborate whether COXderived PGE 2 acts as another potential humoral factor, we incubated MSC-treated PBMCs in the MLR with IDM, a nonselective COX inhibitor. IDM significantly reduced IDO + cells ( Fig. 2A,  2B ) and IDO activity (Fig. 2C) (Fig. 2D, 2E ). L-1-MT synergized with IDM to block the induction of IL-10 + IFN-g + CD4 + cells by MSCs (Fig.  2D, 2E) . Furthermore, neither IDM nor L-1-MT alone could completely abolish the effect of MSCs in suppressing allogeneic PBMC proliferation, whereas IDM combined with L-1-MT abrogated the antiproliferative effect of MSCs (Fig. 2F) . These results suggest that COX-derived PGE 2 and IDO act together to induce CD4 + IL-10 + IFN-g + cells to suppress allogeneic responses. (Fig. 3A) . CD4 + R cells sorted from MSC-treated PBMCs showed a higher level of IL-10 and IFN-g expression than did those from PBMCs not treated with MSCs (Fig. 3A) . The expression of IL-10 and IFN-g in the CD4 + R cells sorted from MSC-treated PBMCs was abrogated by IDM plus L-1-MT (Fig. 3A) . These results suggest that MSCs convert a fraction of CD4 + cells in the allostimulated PBMCs to T R 1-like cells. To confirm that CD4 + R cells possess immunosuppressive properties, we added MSC-treated and control CD4 + R cells to the MLR and analyzed their proliferative activity. CD4 + R cells from MSC-treated PBMCs significantly reduced cell proliferation, whereas CD4 + R cells from control PBMCs had no effect (Fig.  3B) . The suppressive effect of MSC-treated CD4 + R cells was abrogated by IDM plus L-1-MT (Fig. 3B) . Moreover, this suppression was blocked in the presence of neutralizing mAb against IL-10 ( Fig. 3B ). In correlation with the suppression of cell proliferation, IL-10 + IFN-g + CD4 + cells induced by MSC-primed CD4 + R cells were abrogated by IDM plus L-1MT (Fig. 3C, 3D ). Furthermore, MSC-primed CD4 + R cells increased IDO activity in alloactivated PBMCs (Fig. 3E) . These results indicate that MSCs converted CD4 + cells, giving them immunosuppressive properties resembling those of MSCs in vitro.
MSCs convert CD4 + cells into immunosuppressive T R 1-like cells
We next determined whether CD4 + R cells isolated from MSCtreated allostimulated PBMCs are anergic to allostimulation. In the restimulation assay, CD4 + R cells served as responder cells, and the PBMCs from either the original minipig used to induce CD4 + R cells (original S) or other minipigs (third-party S) served as the stimulator cells. CD4 + R cells from the MLR without MSC treatment proliferated in response to the original S and the thirdparty S (Fig. 3F) . In contrast, CD4 + R cells isolated from MSCtreated PBMCs did not proliferate when stimulated with the original or the third-party S (Fig. 3F) . However, CD4 + R cells isolated from MSC-primed allostimulated PBMCs in the presence of IDM plus L-1-MT lost anergy and proliferated in response to the original and the third-party PBMC stimulation (Fig. 3F) + cells, we determined the temporal profile of the MSCsuppressed MLR over 5 d of culture. Allogeneic lymphocyte proliferation increased progressively and achieved a maximum at the end of the 5-d MLR (Fig. 4A) . In the presence of MSCs, PGE 2 levels began to increase as early as 3 h after the MLR (data not shown) and reached a plateau on day 1 (Fig. 4B) . However, IDO activity did not increase significantly until day 3 of the MLR (Fig.  4C) . In parallel, IL-10 + IFN-g + CD4 + cells increased progressively from days 3 to 5 (Fig. 4D) . + R cells. To confirm this hypothesis, we investigated the dependence of PGE 2 in immunosuppression mediated by MSC-primed CD4 + R cells. The PGE 2 level was enhanced significantly in the MSC-treated MLR but was low in the MSC CM (Fig. 5B) . In contrast, PGE 2 was nearly undetectable in the culture of allogeneic MLR treated with MSCprimed CD4 + R cells (Fig. 5B) . Moreover, the addition of IDM attenuated half of the immunosuppressive potency of MSCs, whereas it did not repress the immunosuppressive effects of MSCprimed CD4 + R cells (Fig. 5C) . We further determined whether the exogenous addition of dinoprostone or MPA, an active metabolite of misoprostol (PGE 2 mimetic), enhances the action of MSC-primed CD4 + R cells. Dinoprostone and MPA suppressed lymphocyte proliferation equipotently (Fig. 5D) . A suboptimal concentration (1 ng/ ml) of MPA enhanced the antiproliferative effect of MSC-primed CD4 + R cells. At a cell ratio of 1:1, suppression was comparable to that of MSCs at a cell ratio of 1:1 (Fig. 5E) . However, MPA exerted a lesser effect on MSC-primed CD4 + R cells at a cell ratio of 1:2 (Fig. 5E) . These results suggest that MSC-primed CD4 + R cells are intrinsically deficient in COX-derived PGE 2 and that their immunosuppressive potency can be augmented by PGE 2 supplements. + R cells alone, whereas others received no treatment. Histological examination of the vascular grafts 6 wk after transplantation showed that the untreated allograft was occluded by neointima (Fig. 6) . Administering either PGE 2 or MSCprimed CD4 + R cells alone did not exert a significant suppression of intimal hyperplasia. In contrast, TA was abrogated through concomitant treatment with PGE 2 and MSC-primed CD4 + R cells (Fig. 6) . We next determined the temporal effect of PGE 2 on potentiating anti-TA by MSC-primed CD4 + R cells by administering PGE 2 for the first 14 d only or beginning on day 15. Compared with the group in which PGE 2 was given for 42 d, intimal hyperplasia was evident in the group in which PGE 2 was either given for the first 14 d or administered starting on day 15 ( Fig. 6 versus Supplemental Fig. 3 ). These results, in concordance with the in vitro findings, suggest that administering PGE 2 throughout the allogeneic response is required to potentiate MSCprimed CD4 + R cells to protect the transplanted arterial allografts from TA. Fig. 3A) , they suppressed the proliferation of allodriven PBMCs by 50% in an IL-10-dependent manner (Fig. 3B) . Second, they are hyporesponsive to alloantigens (Fig. 3F) . This anergic characteristic correlates with previous studies wherein T R 1 was reported to have an intrinsically low proliferative capacity (20) . In most recent studies, T R 1-like cells are defined by the coexpression of IL-10 and IFN-g, associated with functional competence in immunomodulation (21, 22 2 CD4 + T cells of tolerant recipients may induce IDO expression in an allograft endothelial cell (38) . Furthermore, IL-10 and IFN-g were found to cooperatively regulate dendritic cell functions toward immune tolerance through the augmentation of IDO (39) . In our MLR model, IDO activity was enhanced by the addition of MSC-primed CD4 + R cells (Fig. 3E ). This finding reinforces the biological significance of the coproduction of IL-10 and IFN-g in immunologic tolerance mediated by T R 1-like cells.
Both PGE 2 (10, 26, 27) and IDO (28, 29) were demonstrated to participate in MSC-mediated immunomodulation. PGE 2 (32) and IDO (34) were suggested to play a role in the induction of IL-10-secreting Tregs. Therefore, it is reasonable to propose that MSCs can induce T R 1 or T R 1-like cells to combat deviated immune responses in a PGE 2 -or IDO-dependent manner. Following this speculation, we found that MSCs blunted allogeneic reactions and expanded IL-10 + IFN-g + CD4 + cells mainly through soluble factors (Supplemental Fig. 2 ). However, inhibitors targeting either PGE 2 production or IDO activity could attenuate the MSC-induced immunomodulation only partially (Fig. 2F) . Only when PGE 2 and IDO were concomitantly blocked could the MSC-expanded IL-10 + IFN-g + CD4 + subpopulation be completely diminished (Fig.  2D, 2E ) and the allogeneic response be restored (Fig. 2F) . Although PGE 2 was reported to promote immune tolerance through the enhancement of downstream IDO expression and activity (40) (41) (42) , this redundancy suggests that MSC-secreted PGE 2 promotes the ontogeny of T R 1-like cells either directly or through IDO. However, in this study, the role of IDO in concerted immunomodulation of MSCs was investigated only by adding an IDO inhibitor in allogeneic MLR in vitro. The significance of IDOinduced KYN pathway metabolites in vivo cannot be confirmed until we demonstrate that IDO inhibition can abrogate MSC-induced long-term allograft patency in our femoral arterial transplantation model.
The clinical use of PGE 2 has been limited by poor oral bioavailability, short half-lives, and significant toxicity profiles. Misoprostol, a synthetic analog of PGE 1 , binds to and activates each of the four heptahelical G protein-coupled E prostanoid receptors normally ligated by the endogenous PGE 2 (43) . The regulatory effects of misoprostol on both innate and adaptive immune systems were proved to be similar to those of natural PGE 2 (44, 45) . Misoprostol, given in the dosage used in this study (200 mg, 4 times daily) and in the presence of conventional immunosuppressants, was reported to reduce acute rejection in renal allografts (46) . Therefore, oral misoprostol can reasonably substitute for PGE 2 in our TA model.
We previously demonstrated that bone marrow-derived MSCs are effective in suppressing TA in a porcine model of femoral arterial transplantation (35) . In this study, we showed that PGE 2 combined with MSC-primed T R 1-like cells may replace MSCs to achieve immune tolerance in TA. This finding raises several implications. First, MSC-primed T R 1-like cells represent only one subset of immunomodulatory cells induced by MSCs. In our study, the potency of MSC-induced T R 1-like cells was 4-fold less than that of MSCs in suppressing the allogeneic MLR (Fig. 5A) . Because we applied the same cell numbers for MSC-induced T R 1-like cells as we did previously for MSCs in the porcine femoral arterial transplantation model, T R 1-like cells might require the assistance of PGE 2 to inhibit TA. Second, PGE 2 and T R 1-like cells may act through independent mechanisms to modulate the immune system. PGE 2 is known to regulate dendritic cell functions in the early priming stage of the allogeneic response (47), whereas T R 1-like cells are more competent in blocking the proliferation of effector T cells and their migration to the target organ (48) . Third, a functional cross-talk probably exists between PGE 2 and T R 1-like cells in immune regulation. PGE 2 was reported to augment IL-10 signaling and biological activity (49) . Under the influence of PGE 2 , IL-10 secreted by pre-existing T R 1-like cells may enhance its downstream effects and promote the de novo induction of more T R 1-like cells. Finally, in the allogeneic MLR modulated by MSCs, the early production of PGE 2 and the expansion of T R 1-like cells at later stages (Fig. 4) suggest that each immunomodulatory mediator must exert its regulatory effects at the appropriate time in vivo to prevent TA. Because T R 1-like cells alone (Fig. 5A ) and PGE 2 alone (Fig. 5D ) partially suppress the allogeneic MLR, both are expected to partially dampen TA when given independently. However, neither T R 1-like cell transfers alone nor PGE 2 administration alone is effective in preventing TA (Fig. 6 ). We speculate that PGE 2 is efficient in regulating allogeneic priming. When T R 1-like cells were provided in the absence of PGE 2 during femoral arterial transplantation, the allogeneic Ag was recognized, and it set in motion an ever-widening immune response that ultimately led to TA. However, the observation that PGE 2 alone is partially effective at alleviating the allogeneic MLR may only be applicable to an in vitro culture with a short duration (5-d coculture period of the MLR). When T R 1-like cells did not act in turn with PGE 2 to modulate allogeneic responses in the femoral arterial transplantation model, the protective effects of PGE 2 were unable to last for 6 wk, and TA ensued. Therefore, it is reasonable to propose that both PGE 2 and T R 1-like cells are indispensable mediators generated by MSCs to maintain long-term immune tolerance. Further studies are required to elucidate the temporal interaction between PGE 2 and T R 1-like cells and to identify their specific targets in the immune system.
We have provided evidence that MSCs induce IL-10 + IFNg + CD4 + T R 1-like cells during allogeneic reactions. Furthermore, MSCs prime a subpopulation of low-proliferative CD4 + cells to commit to coproducing IL-10 and IFN-g and to suppress allogeneic proliferation. We also identified COX-derived PGE 2 and IDO metabolites as soluble factors that induce the generation of T R 1-like cells and mediate the immunomodulatory effects of MSCs synergistically in vitro. Moreover, neither PGE 2 nor T R 1-like cells alone can account for the full suppressive potency of MSCs in vitro; only when both were applied concomitantly in vivo could TA be alleviated. Together, PGE 2 and T R 1-like cells may play nonredundant roles in MSC-mediated immunomodulation against TA. Our findings provide a new approach for the prevention of TA in cardiac transplantation.
